Background
==========

A strong inverse relationship between the plasma concentration of HDL-C and the incidence of coronary heart disease is widely accepted. Few interventions have succeeded to increase plasma HDL levels in HIV-infected pts. NVP has a favorable lipid profile, and clinical trials have suggested that it could have a differential effect on plasma HDL-C levels.

Methods
=======

Prospective, single arm, multicenter study. We included patients on stable antiretroviral therapy with HIV RNA ≤50 copies/mL for at least one year that were switched to a NVP-containing regimen. Patients receiving lipid lowering therapy were excluded. HDL-cholesterol and other lipid parameters at baseline and after 24 weeks of treatment with NVP are compared.

Results
=======

Among 130 pts included in the study, 119 (91%) could be evaluated. BL characteristics: median age 44, female 24%, current smokers 53%. Previous AIDS 29%, CD4 count 502/mm^3^. Time on ARV therapy 42 months. Previous therapy: efavirenz 38%, 3 NRTI 12%, PI 50%. Accompanying nucleosides were tenofovir/emtricitabine in 69%, and abacavir/lamivudine in 31%.

Table [1](#T1){ref-type="table"} shows the 24-week results of lipid profile.

                                               Mean    S. D.   N     p
  ----------------------- -------------------- ------- ------- ----- --------
  Triglycerides (mg/dl)   Previous treatment   213.8   178.3   119   
                                                                     
                          Nevirapine           154.6   95.3    119   \<0.05
                                                                     
  TC (mg/dl)              Previous treatment   203.6   48.0    119   
                                                                     
                          Nevirapine           198.1   40.5    119   0.108
                                                                     
  HDL-C (mg/dl)           Previous treatment   43.8    14.6    119   
                                                                     
                          Nevirapine           49.3    16.8    119   \<0.05
                                                                     
  TC/HDL-C                Previous treatment   5.1     1.9     119   
                                                                     
                          Nevirapine           4.3     1.3     119   \<0.05
                                                                     
  LDL (mg/dl)             Previous treatment   120.2   38.1    107   
                                                                     
                          Nevirapine           119.2   32.7    107   0.705
                                                                     
  VLDL (mg/dl)            Previous treatment   35.1    19.4    25    
                                                                     
                          Nevirapine           23.6    12.6    25    \<0.05

At 24 week, the proportion of patients with HDL-C\>40 mg/dl were 69.7% (95%CI 60.7-77.8), compared to 52.1% (95%CI 42.8-61.3) before taking NVP (p\<0.01). The Framingham risk score decreased from 7.6 to 6.6 (p\<0.05) after switching to NVP.

Conclusions
===========

Switching to NVP-containing regimens in patients on stable therapy is associated with a significant increase in HDL-C and decrease in TC/HDL-c, with an overall improvement in the Framingham score.
